480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6
oleh: Susanna Ulahannan, Manish Patel, Gerald Falchook, David Spigel, Babar Bashir, Christine Duffy, Daniela Maier, Hisaya Azuma
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.